emilia/hemoterapija

Veza se sprema u međuspremnik

Odaberite vrstu sortiranja

Page 1 od 23 rezultati

Evaluation of the anti-inflammatory and urotoxicity ameliorative effects of γ-humulene containing active fraction of Emilia sonchifolia (L.) DC.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

In folklore medicine, the plant Emilia sonchifolia, belonging to the family Asteraceae, is used for treating tumour and inflammation. In our previous studies, we have done a thorough phytochemical investigation of E. sonchifolia with a report on its potent antimetastatic activity. Further, we

The pre-emptive screening of multiple polymorphisms in gene-encoding dihydropyrimidine dehydrogenase (DPD) improve prevention of toxicity on patients candidate for fluoropyrimidine based-chemotherapy. An experience of the Reggio Emilia Cancer Center.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

The antibody-drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Approval of this drug was based on progression-free survival and interim overall survival data from the phase 3

Key factors influencing lung cancer survival in northern Italy.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

OBJECTIVE Lung cancer is a major cause of cancer death worldwide. The aims of this study were to analyze presentation, treatment and survival for lung cancer in northern Italy, and identify factors influencing survival. METHODS A total of 1180 lung cancer cases diagnosed in four north Italian cancer

[Adjuvant radiotherapy in rectal neoplasms. Survival analysis,local control, prognostic factors and toxicity].

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

January 1985 to June 1991, seventy-five patients affected with surgically treated rectal cancer received adjuvant postoperative irradiation at the Radiation Therapy Department of the Ospedale S. Maria Nuova, Reggio Emilia, Italy. Forty-seven patients had Astler-Coller B2-B3 lesions and 28 had stage

[Human cystic hydatidosis in Italy: a public health emergency? Past to present].

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Starting from 1991 the Central Office of Statistics ISTAT, according to changed regulations on notification of infective diseases, stopped reporting official national data on human hydatidosis. On the other hand until then notified data, concerning only about a hundred cases per year in mean during

Major clinical research advances in gynecologic cancer in 2012.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Ten topics were chosen among major clinical research achievements in gynecologic oncology in 2012. For ovarian cancer, comprehensive review of the history of bevacizumab studies was followed by poly adenosine diphosphate [ADP]-ribose polymerase (PARP) inhibitors and other molecular targeted agents

Breast Cancer 2012 - New Aspects.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Treatment options as well as the characteristics for therapeutic decisions in patients with primary and advanced breast cancer are increasing in number and variety. New targeted therapies in combination with established chemotherapy schemes are broadening the spectrum, however potentially promising

Long-time Response with Ado-trastuzumab Emtansine in a Recurrent Metastatic Breast Cancer.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Breast cancer is the most common cancer in a woman with a five-year survival of patients with metastatic disease is estimated at 23%. Ado-trastuzumab emtansine (T-DM1) is a HER2-antibody drug conjugate currently approved for the treatment of HER2-positive pre-treated metastatic breast cancer (BC).

Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Trastuzumab emtansine is an antibody-drug conjugate comprised of the receptor tyrosine-protein kinase erbB-2 (HER2) antibody trastuzumab, and a derivative of the cytostatic agent maytansinoid DM1, covalently linked by a thiol linker. The drug was developed in an attempt to overcome trastuzumab

Regional inequalities in cancer care persist in Italy and can influence survival.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

BACKGROUND Population-based cancer registry studies of care patterns can help elucidate reasons for the marked geographic variation in cancer survival across Italy. The article provides a snapshot of the care delivered to cancer patients in Italy. METHODS Random samples of adult patients with skin

The first 2 years of colorectal cancer screening in Ferrara, Italy.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

We report on the first screening round in the District of Ferrara, a region of Emilia-Romagna, carried out between March 2005 and March 2007 to illustrate the effort of colorectal cancer (CRC) screening from administration and information to therapy and follow-up. After invitation of 38 344 persons

Neoadjuvant therapy for breast cancer.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I-III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area.Data from the High Resolution Study conducted in 7

Clinical governance network for clinical audit to improve quality in epithelial ovarian cancer management.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

BACKGROUND Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Several hospitals throughout the region provide primary treatment for these patients and it is well know that treatment quality is correlated to the hospital that delivers. The aim of this study was to investigate

Factors influencing return to work of cancer survivors: a population-based study in Italy.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Little is known about return to work (RTW) of cancer survivors (CSs) in Central and Southern Europe. This study investigates the RTW rate of Italian CSs, describes their sick leave (SL) pattern, and explores factors affecting their RTW process.A

Prethodni
1
2
Sljedeći

Pridružite se našoj
facebook stranici

Herbal & Natural Medicine

Najkompletnija baza ljekovitog bilja potpomognuta naukom

Radi na 55 jezika
Biljni lijekovi potpomognuti naukom
Prepoznavanje biljaka po slici
Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
Pročitajte naučne publikacije povezane sa vašom pretragom
Pretražite ljekovito bilje po učincima
Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima